Arrowhead Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a commercial-stage biotechnology company specializing in the development of novel medicines that treat intractable diseases by silencing the genes that cause them. Utilizing its proprietary Targeted RNAi Molecule (TRiM™) platform, Arrowhead designs therapies that leverage the natural pathway of RNA interference (RNAi) to achieve deep and durable knockdown of disease-causing proteins. The company's business model has successfully transitioned from a pure-play research and development platform to a vertically integrated commercial entity. This shift was catalyzed by the FDA approval of REDEMPLO® (plozasiran) on November 18, 2025, as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome (FCS). Arrowhead's pipeline spans high-value therapeutic areas, including cardiometabolic, pulmonary, hepatic, and central nervous system (CNS) disorders, supported by both independent development and strategic partnerships with global pharmaceutical leaders.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Independently commercializing REDEMPLO (plozasiran) in the U.S. for FCS while preparing for global launches in Europe, Canada, and Australia, and expanding the indication into severe hypertriglyceridemia (sHTG).
Expected impact: Establishes Arrowhead as a commercial-stage entity and drives long-term product sales, with sHTG representing a multi-billion dollar blockbuster opportunity.
Advancing the Targeted RNAi Molecule (TRiM) platform beyond liver-targeted therapies into extra-hepatic tissues, specifically targeting the central nervous system (CNS) using a proprietary blood-brain barrier (BBB) delivery system, and adipose tissue for obesity.
Expected impact: Validates the versatility of the TRiM platform to address neurodegenerative diseases (e.g., Alzheimer's via ARO-MAPT) and metabolic disorders (e.g., obesity via ARO-INHBE and ARO-ALK7).
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Outlicenses ARO-PNPLA3, a clinical-stage RNAi therapeutic for metabolic dysfunction-associated steatohepatitis (MASH), to a leader in the MASH space, allowing Arrowhead to focus resources on its core cardiometabolic pipeline.
Terms: $25 million upfront payment, with eligibility to receive up to $975 million in development, regulatory, and sales milestones, plus tiered royalties ranging from high-single digits to mid-teens.
Collaborating on ARO-SNCA, an investigational siRNA therapy targeting alpha-synuclein for synucleinopathies like Parkinson's disease, and additional targets utilizing Arrowhead's TRiM platform.
Terms: $200 million upfront payment, with eligibility to receive up to $2 billion in development, regulatory, and sales milestones, plus tiered royalties.
Collaborating on multiple clinical and preclinical programs targeting rare neuromuscular and pulmonary diseases, including ARO-DUX4, ARO-DM1, ARO-MMP7, and ARO-ATXN2.
Terms: $500 million upfront payment, $325 million equity investment, $250 million in annual installments ($50 million/year over 5 years), and up to $300 million in near-term payments, plus milestones and royalties.
Sanofi acquired the exclusive rights to develop and commercialize plozasiran in Greater China from Arrowhead's subsidiary Visirna, leveraging Sanofi's established commercial infrastructure in the region.
Terms: $130 million upfront payment to Visirna, with eligibility for $265 million in approval milestones, plus royalties on net sales.